ArticleNature communications2025
Molecular subtyping of hypertensive disorders of pregnancy.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early gestational prediction of spontaneous preterm birth using a validated three-protein serum biomarker panel.BMC medicine · 2026Pooled it
- To bridge the evidence gap in women's health, look at the real world.Nature medicine · 2026Article
- The pathophysiology of pre-eclampsia.Nature reviews. Nephrology · 2026Review
- First-trimester multi-modal cell-free DNA analysis for prediction of preterm and term preeclampsia.AJOG global reports · 2026Article
- A first-trimester mechanistic framework integrating three Physiopathologic biomarker domains for pre-eclampsia classification.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
- Health in translation: a workshop model for health literacy and lay science communication.Advances in physiology education · 2026Article
- Clinical and Molecular Differences of Hypertensive Disorders During Pregnancy.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Plasma RNA-Based Dual Screening for Early/Extreme Spontaneous Preterm Birth and Early Onset Preeclampsia to Enable Prevention.Diagnostics (Basel, Switzerland) · 2026Article
- Protein networks are influenced by maternal BMI and differentiate preterm birth types.Communications medicine · 2026Article
- From empirical regimens to precision prophylaxis: mechanism-based targeting of preeclampsia phenotypes.Frontiers in pharmacology · 2026Review
- Oxidative dyslipidemia in early pregnancy: integrating atherogenic index of plasma (AIP) and uric acid (UA) to refine preeclampsia risk stratification.Frontiers in pharmacology · 2026Article
- Incremental prognostic value of the fibrinogen-to-albumin ratio for adverse perinatal outcomes in preeclampsia: a dual-center retrospective cohort study.Frontiers in endocrinology · 2026Article
- Cell type inference in cell-free nucleic acid liquid biopsy.Nature biotechnology · 2025Review
- Human placentation: foundations and implications for reproductive endocrinology and infertility.Systems biology in reproductive medicine · 2025Review
- Multi-omic insights of preeclampsia and cardiovascular health outcomes.Communications medicine · 2025Review
- Maternal plasma cell-free RNA as a predictor of early and late-onset preeclampsia throughout pregnancy.Nature communications · 2025Article
- Myo-inositol to Prevent Pregnancy Complications: Valuable Evidence Amid Complex Etiologies.JAMA · 2025Article
- Raised Leptin and Pappalysin2 cell-free RNAs are the hallmarks of pregnancies complicated by preeclampsia with fetal growth restriction.Nature communications · 2025Article
- Utility of the US Preventive Services Task Force for Preeclampsia Risk Assessment and Aspirin Prophylaxis.JAMA network open · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertensive disorders of pregnancy (HDP), including preeclampsia, affect 1 in 6 pregnancies, are major contributors to maternal morbidity and mortality, yet lack precision medicine strategies. Analyzing transcriptomic data from a prospectively-collected diverse cohort (n = 9102), this study reveals distinct RNA subtypes in maternal blood, reclassifying clinical HDP phenotypes like early/late-onset preeclampsia. The placental gene PAPPA2 strongly predicts the most severe forms of preeclampsia in individuals without pre-existing high risk factors, months before symptoms, and its overexpression correlates with earlier delivery in a dose-dependent manner. Further, molecular subtypes characterized by immune genes are upregulated in less severe forms of HDP. These results reclassify HDP clinical phenotypes into two distinct molecular subtypes, placental-associated or immune-associated. Validation performance for placental-associated HDP yields an AUC of 0.88 in the advanced maternal age population without pre-existing high risk factors. Molecular subtypes create new opportunities to apply precision-based medicine in maternal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.